24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
FALSOLIEVA 250 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | FALSOLIEVA 250 MG |
|---|---|
| Composition | Fulvestrant Injection 250 MG |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
Fulvestrant Injection 250 MG (Fulvestrant Injection 250 MG) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
Falsolieva 250 mg contains Fulvestrant, a hormonal anticancer medicine classified as a Selective Estrogen Receptor Degrader (SERD). It works by binding to estrogen receptors and causing their degradation, thereby blocking estrogen-driven growth of hormone-dependent breast cancer cells.
Fulvestrant Injection is indicated for treatment of:
Hormone receptor–positive (ER+) breast cancer
Locally advanced or metastatic breast cancer in postmenopausal women
Breast cancer after progression on anti-estrogen therapy (e.g., tamoxifen, aromatase inhibitors)
Common side effects:
Injection-site pain
Hot flashes
Nausea
Fatigue
Headache
Joint or muscle pain
Serious side effects:
Liver function abnormalities
Thromboembolic events (rare)
Hypersensitivity reactions
Use with caution in patients with liver impairment.
Standard recommended dose:
500 mg intramuscularly
Dosing schedule:
Day 1: 500 mg
Day 15: 500 mg
Day 29 and monthly thereafter: 500 mg
Given as two separate IM injections (250 mg each), one in each gluteal muscle.